Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00705185 · ClinicalTrials.gov registry record

Exploring a Potential Blood Test to Diagnose Major Depressive Disorder

A clinical trial, sponsored by Massachusetts General Hospital.

Completed
Registry status
120
Enrollment target

NCT00705185: Completed study, sponsored by Massachusetts General Hospital.

NCT00705185 is a clinical trial that has completed, run by Massachusetts General Hospital. The registered enrollment target is 120 participants. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00705185 has completed, sponsored by Massachusetts General Hospital.

COMPLETED
Registry status
120 participants
Enrollment target

Study Summary

The purpose of this study is to develop a blood test for major depression and measure the effects of ziprasidone monotherapy on these markers. Specific Aim: Using a multiplex biomarker assay we will measure levels of 16 biomarkers in patients with MDD enrolled in this ancillary study (adjunct to study NCT00555997) and compare these results to those of healthy controls" (defined as research subjects who have not met criteria for any lifetime Axis-I disorder (DSM-IV)) from an existing dataset at PHB.

Trial Details

FieldValue
Enrollment Target 120 participants
Start Date 2008-04
Est. Completion 2010-06

Sponsor

Massachusetts General Hospital

2,032 total trials

What the Registry Record Tells You About NCT00705185

The ClinicalTrials.gov registry entry for NCT00705185 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Massachusetts General Hospital, which has 2,032 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 0 interventions.

NCT00705185 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00705185 about?

NCT00705185 is a clinical study titled "Exploring a Potential Blood Test to Diagnose Major Depressive Disorder". The purpose of this study is to develop a blood test for major depression and measure the effects of ziprasidone monotherapy on these markers. Specific Aim: Using a multiplex biomarker assay we will measure levels of 16 biomarkers in patients with MDD enrolled in this ancillary study (adjunct to st...

What is the current status of trial NCT00705185?

This trial is currently completed. The enrollment target is 120 participants. The study started on 2008-04. Estimated completion is 2010-06.

Who is sponsoring clinical trial NCT00705185?

This trial is sponsored by Massachusetts General Hospital, which has 2,032 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.